227 results about "Low glucose" patented technology

A health-monitoring device assesses the health of a user based on levels of two analytes in a biological fluid. A first analyte that is utilized to assess a user's health is a fat metabolism analyte, such as ketones, free fatty acids and glycerol, which is indicative of fat metabolism. A second analyte that is utilized is a glucose metabolism analyte, such as glucose. The levels of the two analytes may be used to assess insulin sensitivity, to detect both recent hypoglycemia and the cause of high glucose levels, and/or to guide therapeutic intervention. The dual analyte model may calculate a discrepancy between an actual insulin activity level and a theoretical insulin activity level. The dual analyte model of the present invention may be used to identify individuals at risk for metabolic syndrome, insulin resistance and non-insulin dependent diabetes, and allows monitoring of the progression of those disease states, as well as progress made by therapeutic interventions.

A system and method provides a glucose report for determining glycemic risk based on an ambulatory glucose profile of glucose data over a time period, a glucose control assessment based on median and variability of glucose, and indicators of high glucose variability. Time of day periods are shown at which glucose levels can be seen. A median glucose goal and a low glucose line provide coupled with glucose variability provide a view into effects that raising or lowering the median goal would have. Likelihood of low glucose, median glucose compared to goal, and variability of glucose below median provide probabilities based on glucose data. Patterns can be seen and provide guidance for treatment.

A system, computer program product, method and algorithm for evaluation of blood glucose variability—one of the most important parameters of diabetes management. An embodiment of the method may use routine self-monitoring blood glucose (SMBG) data collected over a period of 2-6 weeks, for example, based on a theory of risk analysis of blood glucose data. One aspect may include a method, system and computer program product for computing the Average Daily Risk Range (ADRR)—a measure of overall glucose variability. Another aspect may include a method, system, and computer program product for estimating separately the glucose variability in the hypoglycemic range via a Low BG Index (LBGI) and the glucose variability in the high BG range via High BG Index (HBGI) followed by a combination of the two indices into a single variability display.

This invention relates to a nutritional intervention composition for enhancing satiety prior to a meal and extending satiety after a meal. The nutritional intervention composition decreases food intake producing weight loss over time. The composition consists of Niacin, Vitamin B6, Calcium, Phosphorous, Magnesium, Chromium, Chitosan, Fenugreek, Ginseng, White willow bark, Garcinia cambogia, Aloe Vera gel powder, Momordica charantia, Griffonia simplicifolia, Lagerstroemia speciosa and Vanadyl sulfate. The invention does not require stimulants or anabolic ingredients. There are three phases of activity within the composition. One, enhanced satiety through elevated serotonin. Two, improved carbohydrate metabolism, reduced blood glucose and slowed gastric emptying. Three, enhanced fiber binding of lipids and excess bile acids.

A system and method to provide guidance for diabetes therapy includes determining glycemic risks based on an analysis of glucose data. The analysis includes visualization of a glucose median, the variability of glucose in a patient, and the risk of hypoglycemia. An Advanced Daily Patterns report includes a visualization of an ambulatory glucose profile and a glucose control measure. The glucose control measure provides a highly visible and understandable display of the glucose condition of a patient visually expressed in the categories of low glucose, median glucose, and glucose variability.

Disclosed is a novel food product characterized by a low glucose or glucose free content, a balanced functional fat content, and a proactive agent aimed for the diabetic and diabetic-prone populations. The food product of the invention is a functional food which may be used clinically to lower the lipid level in people suffering from an imbalanced lipid profile and which may progress towards diabetes complications and coronary vascular disorders. In particular embodiments the proactive agent can be any of a naturally occurring lipid, a synthetic or mimetic lipid which is not digestible by humans and interferes with body weight gain/loss, plant extracts and substances derived therefrom, antioxidants, animal-derived substances, minerals and pharmaceuticals, and any mixture thereof.

The invention belongs to the technical field of affinal drug and diet formulas and new resource food, and particularly provides blood fat-reducing medical science formula food, specific medical formula food or non-specific medical formula food. The formula food is prepared by performing reasonable compatibility on multiple affinal drug and diet traditional Chinese medicines according to the traditional Chinese medicine essence theory and mixing drug-diet dual purpose traditional Chinese medicine extract essence extracted through a semi-bionic extraction method, multiple microencapsulated probiotics, oligopeptides extracted through biological enzymolysis, prebiotics, amino acid, carbohydrate, fat with a health-care function, multiple vitamins and mineral substances according to the requirements of a 'special medial-purpose formula food general rule' by combining the constitutive characters of hyperlipidemia patients; the formula food not only can serve as a single nutrition source to meet the nutritional requirement of the hyperlipidemia patients, but also achieves the effects of reducing total cholesterol, reducing serum triglyceride, reducing an atherosclerosis index, reducing blood pressure, reducing blood sugar, reducing fat to lose weight and enhancing the immunity.

A means for replacing common sugars (particularly sucrose) in a range of foods that maximizes sugar-like taste, texture and other key properties of sugar while minimizing the undesirable traits such as blood sugar response, digestive side effects, high caloric content and aftertastes. Various differing ratios and combinations of high intensity sweetening agents, high molecular weight bulking agent(s), substantially non-digestible sugar(s), and low molecular weight sugar alcohol(s) are used for various applications such as tabletop sugar substitute, frozen deserts, condiments, baked goods, chocolate and confectionaries have different formulations. These sugar replacement approaches are highly relevant to the production of diabetic-friendly foods, diet and/or reduced calorie foods, non-cariogenic (tooth-friendly) foods and other sweet, low-glycemic foods.

Systems and methods are described providing a hepatic recycling glucose tolerance test for the diagnosis of types and subtypes of diabetes mellitus and other hyperglycemic or hypoglycemic conditions. A method is also provided for screening candidate drugs for treating various types of abnormal glucose metabolism and to monitor whether the course of treatment is effective. The method also allows the correlation of gene activity, hormone and metabolite levels with glucose flux and recycling and an assessment of the degree of hepatic insulin resistance. The method utilizes a preferably non-radioactive stable labeled glucose to asses the relative rates of carbon flow in the liver and provides a hepatic recycling constant that is a measure of the relative rate of glucose recycling. The labeled glucose may be introduced to the patient orally, intravenously or by intraperitoneal administration for the desired effect.

The invention discloses a method for preparing low sugar preserved apricots. Key technical parameters which can influence the quality of the low glucose preserved apricots are determined by using dried apricots or fresh apricots as raw materials and adopting novel nutritive sweeteners with specific physiological functions, i.e., maltooligosaccharides as a filler and using fructose syrups as a sweetener, wherein in the primary vacuum sugar permeability process, the concentration of sugar solution is in the range of 30-35 percent, the time is 20min, the sugar solution has a temperature of 60 DEG C, the vacuum degree is 0.07Mpa, and the sugaring time under normal pressure is in the range of 10-15 hours; in the secondary vacuum sugar permeability process, the concentration of the sugar solution is in the range of 40-45 percent, the time is 20min, the sugar solution has a temperature of 60 DEG C, the vacuum degree is 0.07MPa, and the sugaring time under normal pressure is in the range of 10-15hours; and color, plumpness, sugar content and shearing force of a product are used as integrated quality evaluation indexes, so that the method for preparing the low sugar preserved apricots is determined. The preserved apricots prepared by adopting the method provided by the invention not only has low total sugar content, but also has specific nutritional value and has wide applicable consumer range.

The invention discloses a method for producing a controlled/slow release starch derivative with hypoglycemia response characteristics, and belongs to the technical field of the production of functional food additives. The method utilizes a conventional industrial natural polymer to obtain the controlled/slow release starch derivative with the hypoglycemia response characteristics through micro-encapsulation embedding technology. The method adopts emulsification/internal gelatination technology, takes commercialized starch with different sources as a core material, and takes a compound of canageenen or sodium alginate and chitosan as a wall material to obtain a starch derivative with a particle size of between 10 and 150mu m through micro-encapsulation embedding treatment. The content of temperature-resistant slowly digestible starch (SDS) is remarkably improved (more than or equal to 15 percent) relative to native starch in the starch derivative, and the change range of the content thereof does not exceed 3 percent after high-pressure cooking treatment. A glycemic index (GI) is lower than 55 percent. The starch derivative not only can be taken as a functional ingredient to be added to develop novel slowly digestible hypoglycemia food, but also can be taken as a carrier material of stabilization and targeted controlled/slow release of functional factors such as probiotics, active polypeptide, protein, grease, vitamin and the like.

The invention relates to a method for high-efficiency fermentation production of L-glutamic acid. The method can solve the problems of lower acid production, low glucose-acid conversion rate, and the like of the prior production process. The method comprises the following steps: a biotin auxotroph strain is taken as a production strain, according to a certain proportion, a plurality of nutritional components are prepared into a culture medium with rich and balanced nutrients as the fermentation culture medium, the dissolved oxygen is controlled on the appropriate level through the regulation of the stirring speed of a fermentation tank and the wind amount, the pH is controlled by feeding ammonia water, and the residual sugar is controlled on the lower level by feeding glucose solution with a certain concentration, and the fermentation is stopped till 32h. The method can shorten the whole fermentation cycle and greatly improve the yield (more than 150g/l) and the conversion rate (more than 60 percent) of the L-glutamic acid under the situation of not increasing any additional equipment and manpower investment, the whole process has simple operation and lower production cost, thereby being very applicable to industrial production.

A composition of all natural compounds that provides a sweet flavor profile and is high in fiber and low glycemic for use in foods and/or beverages, and/or for use as a sugar substitute.

The invention discloses separation, purification and identification methods of human amnion mesenchymal stem cells. The separation method of hAMSCs (human amnion mesenchymal stem cells) comprises the following steps: fragmentating human amnion; and carrying out two-step rotating digestion with trypsin of EDTA (ethylene diamine tetra-acetic acid) and collagenase of DNaseI, filtering with a steel mesh and collecting cell filtrate namely separated original hAMSCs. The purification method of hAMSCs comprises the following steps: incubating original hAMSCs with an LG (low glucose)-DMEM (dulbecco modified eagle medium) culture medium in a CO2 incubator; removing amnion epithelial cells which do not perform complete adherence growth under an inverted microscope; replacing a new culture medium on the third day; digesting with a trypsin-EDTA solution after cell converge degree reaches 80-90%; and collecting cells so as to obtain high-purity hAMSCs. The identification method of hAMSCs comprises the following steps: identifying hAMSCs and the amnion epithelial cells by adopting immunocytochemical staining vimentin and CK19; and detecting expressions of CD29, CD44, CD166, CD34 and CD45 by adopting a flow cytometry. The separation and purification methods disclosed by the invention have the advantages of high yield, high activity and high purity of hAMSCs; and the identification method is simple, convenient and precise.

The invention provides a compound and application of the compound and the pharmaceutically acceptable salt thereof or a stereo isomer or a prodrug molecule thereof in preparing a medicament for treating or preventing metabolic diseases, wherein the compound has the structural characteristic of a general expression I and is used as a novel fat cell type fatty acid binding protein FABP inhibitor. The compound having the structural characteristic of the general expression I can provide a new selection for the clinical prevention and treatment of the following diseases: 1. type II diabetes, 2. hyperglycemia, 3. hypoglycemia tolerance, 4. insulin resistance, 5. adiposity, 6. lipid turbulence, 7. blood-lipoid imbalance, 8. hyperlipaemia, 9. hypertriglyceridemia, 10. hypercholesterolemia, 11. low high-density protein level, 12. overhigh low-density protein level, 13. atherosclerosis and secondary diseases thereof, 14. hemadostenosis, 15. abdominal obesity, 16. a metabolic syndrome and 17. fatty liver.

The invention provides a composition with an auxiliary blood sugar reduction efficacy, and a preparation method and application thereof, and relates to the technical field of medical care. The composition is mainly prepared from the raw materials in parts by weight: 20 to 50 parts of L-arabinose and a bitter gourd preparation, wherein the bitter gourd preparation comprises any one material of 15 to 35 parts of bitter gourd powder, 10 to 50 parts of bitter gourd extracts and 1 to 5 parts of bitter gourd polypeptide. The composition has the advantages that on one hand, the effects of controlling the conversion and adsorption of the human body on sugar and enhancing the insulin are achieved, and the blood sugar can be reduced in a synergistic way; and on the other hand, the recipe selects raw materials with simple ingredients, so that the absorption is easy, and the dependence cannot be easily generated. The preparation method of the composition is characterized in that the raw materials and a bonding agent are mixed and are prepared into granules. The preparation method has the advantages that the technological process is short; the operability is high; and the industrial production is facilitated.

The present invention discloses a preparation method of slowly-digestible starch-based recombinant rice with a low glycemic index, and belongs to the technical field of food processing. After a high-temperature fluidization technology is used to conduct a non-crystallizing treatment of a solid-phase broken rice raw material in a short time, materials are subjected to a one-step reactive extrusiontechnology, enzyme-adding enzymatic hydrolysis and an esterification treatment are combined, and the recombinant rice with high slowly-digestible starch content and low glycemic index is obtained. Therecombinant rice prepared by the one-step shaping extrusion technology is suitable for consumption of patients with type II diabetes. At the same time, the preparation method increases added value ofagricultural and sideline products, reduces production cost, and improves production efficiency.

The invention provides bread with a low glycemic index (GI) and a making method thereof. The making method is characterized by grinding 5-30 parts by weight of black rice to obtain black rice powder; weighing 1-10 parts by weight of dried seaweed, soaking the dried seaweed in water, washing the seaweed, adding a defined amount of water and crushing the seaweed into seaweed paste, taking and putting 1-3 parts by weight of dried yeast in a container, pouring in warm water, stirring the materials uniformly to activate the yeast, mixing the seaweed paste, the black rice powder, activated yeast liquid, 100 parts by weight of strong wheat flour and 40-75 parts by weight of water, mixing and stirring the materials until the dough is mature and then preparing the stirred dough into bread by adopting the conventional fermenting, proofing and baking processes. Compared with the prior art, the bread has a low GI value and is suitable for the patients with low glucose tolerance and the diabetic patients.

The invention discloses a making method of health dendrobe liquor, belonging to the field of food processing. The making method is characterized in that dendrobium stem utilized as a raw material and auxiliary materials including poria, tuber fleeceflower stem, radix asteris, Xylariasp, orchis are subjected to processing procedures of wall-breaking crushing, extraction, sealed fermentation, post-fermentation, ultrafiltration membrane clarification and aging, thus obtaining the finished health dendrobe liquor. The health dendrobe liquor is high in nutritive value, special in aroma and mellow and mild in taste, further has the efficacies of tonifying stomach, regenerating body fluid, clearing heat, easing pain, reducing blood glucose and prolonging life and is a health-nourishing health product with extremely high nutritive value and mellow, mild, natural and pure aroma.

The invention relates to spirulina-containing extruded rice with low GI (glycemic index). The spirulina-containing extruded rice comprises raw materials in parts by weight as follows: 30-50 parts of bitter buckwheat, 20-40 parts of oat meal, 5-10 parts of soybean powder, 5-10 parts of white hyacinth bean powder, 1-3 parts of spirulina powder, 1-5 parts of yam flour, 10-15 parts of dietary fiber, 0.5-1.5 parts of vitamins and 0.5-1.5 parts of minerals. Various cereal materials with low GI are taken as a substrate, the added spirulina powder has a function of assisting in reduction of blood sugar, the added dietary fiber facilitates growth of probiotics in intestinal tracts and delays the food digestion rate in gastrointestinal tracts, and rapid increase of postprandial blood sugar is delayed to a certain extent. Active ingredients such as various vitamins, the minerals and the like are widely applied in the health care field, reproduced rice with low GI is prepared through reasonable compounding with an extrusion technology, and a novel diet mode is provided for people with obesity, high glucose and diabetes as well as people requiring low-GI food.

The invention discloses a GLP-1 peptide, whose general formula is HX1EGTFTSDX2SSYLEGQAAKX3FIX4WLVKGR (formula I), wherein X1 is Ala, Gly or Val; X2 is Val, Leu or Ala; X3 is Leu or Ser; X4 is Glu or Asn.

The invention discloses a method for preparing and preserving umbilical arterial and vein vascular peripheral stem cells. The umbilical arterial and vein vascular peripheral stem cells are cultured by a cell culture fluid (DMEM low glucose, 10% of fetal calf serum and 1% of penicillin-streptomycin double anti-body). The operation is carried out under strict aseptic conditions; and after umbilical cord collection, the inconvenience caused by blood coagulation is effectively avoided by use of an anticoagulant. Compared with a conventional coating method, the method disclosed by the invention has the advantages that umbilical perivascular sourced mesenchymal stem cells with higher purity are obtained; allergic reaction and cross infection caused by animal-based protein can be avoided since digestive enzymes are not adopted; and the umbilical perivascular stem cells separated by a non-zymogen digestion method have higher positive rate than that of the Wharton's jelly sourced mesenchymal stem cells.